<SEC-DOCUMENT>0001213900-25-082964.txt : 20250902
<SEC-HEADER>0001213900-25-082964.hdr.sgml : 20250902
<ACCEPTANCE-DATETIME>20250902090751
ACCESSION NUMBER:		0001213900-25-082964
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250902
FILED AS OF DATE:		20250902
DATE AS OF CHANGE:		20250902

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inspira Technologies OXY B.H.N. Ltd
		CENTRAL INDEX KEY:			0001837493
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40303
		FILM NUMBER:		251283242

	BUSINESS ADDRESS:	
		STREET 1:		HATIDHAR 2
		STREET 2:		11TH FLOOR
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4366504
		BUSINESS PHONE:		972-9-9664488

	MAIL ADDRESS:	
		STREET 1:		HATIDHAR 2
		STREET 2:		11TH FLOOR
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4366504
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0255477-6k_inspira.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the Month of September 2025 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-40303</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Inspira Technologies Oxy B.H.N. Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Translation of registrant&rsquo;s name into
English)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2 Ha-Tidhar St.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ra&rsquo;anana 4366504, Israel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of principal executive office)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>
Form 20-F&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>&nbsp;Form
40-F</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Symbol; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P><P STYLE="font: 10pt Symbol; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 2, 2025, Inspira
Technologies Oxy B.H.N. Ltd., or the Registrant, issued a press release titled &ldquo;Top U.S. Honor Roll Hospital Expands Use of Inspira
ART100 System to Lung Transplant Procedures,&rdquo; a copy of which is furnished as Exhibit 99.1 with this report of foreign private issuer
on Form 6-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The first, second, and fourth
paragraphs and the section titled &ldquo;Forward-Looking Statements&rdquo; in the&nbsp;press release are incorporated&nbsp;by reference
into the Registrant&rsquo;s Registration Statements on Form F-3 (Registration Nos.&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1837493/000121390022046430/ea164081-f3_inspiratech.htm">333-266748</A>,&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1837493/000121390025004023/ea0227763-f3_inspira.htm">333-284308</A>,
and <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390025072618/ea0251967-f3_inspira.htm">333-289324</A>) and Form&nbsp;S-8
(Registration Nos.&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1837493/000121390021044780/ea146415-s8_inspiratech.htm">333-259057</A>,&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1837493/000121390024023044/ea0201791-s8_inspira.htm">333-277980</A>
and <A HREF="http://www.sec.gov/Archives/edgar/data/1837493/000121390025020699/ea0233153-s8_inspira.htm">333-285565</A>), filed with the
Securities and Exchange Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted,
to the extent not superseded by documents or reports subsequently filed or furnished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; width: 9%; border-bottom: black 1.5pt solid"><B>Exhibit No.</B></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 90%; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: justify">99.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea025547701ex99-1_inspira.htm">Press Release issued by Inspira Technologies Oxy B.H.N. Ltd. on September 2, 2025, titled &ldquo;Top U.S. Honor Roll Hospital Expands Use of INSPIRA&trade; ART100 System to Lung Transplant Procedures.&rdquo;</A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P><P STYLE="font: 10pt Symbol; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><B>Inspira Technologies Oxy B.H.N. Ltd.</B></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Date: September 2, 2025</TD>
    <TD>By:&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid">/s/ Dagi Ben-Noon</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 5%">Name:&nbsp;</TD>
    <TD STYLE="width: 32%"> Dagi Ben-Noon</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea025547701ex99-1_inspira.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY INSPIRA TECHNOLOGIES OXY B.H.N. LTD. ON SEPTEMBER 2, 2025, TITLED "TOP U.S. HONOR ROLL HOSPITAL EXPANDS USE OF INSPIRA TM ART100 SYSTEM TO LUNG TRANSPLANT PROCEDURES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Top U.S. Honor Roll Hospital Expands Use of
INSPIRA&trade; ART100 System to Lung Transplant Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">RA&rsquo;ANANA,
Israel, September 2, 2025 -- Inspira&trade; Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (&ldquo;<B>Inspira,</B>&rdquo; <B>&ldquo;Inspira
Technologies</B>,&rdquo; or the &ldquo;<B>Company</B>&rdquo;), a pioneer in innovative life-support and diagnostic technologies, today
announced that a top U.S. hospital, has expanded its clinical use of the INSPIRA&trade; ART100 system to lung transplantation procedures,
one of the most demanding applications in advanced respiratory care. The hospital was included in the U.S. News &amp; World Report 2025-2026
Best Hospitals Honor Roll of the nation&rsquo;s top 20 hospitals, and has multiple specialties consistently ranked among the top five
nationwide</FONT>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This clinical expansion follows the hospital&rsquo;s positive experience
with the ART100 system in prior clinical use. The decision by one of the nation&rsquo;s most highly ranked hospitals to extend the use
of Inspira&rsquo;s technology into such a critical and complex surgical procedure provides strong external validation of the system&rsquo;s
performance and clinical value. Expanding the application of the ART100 into lung transplantation highlights its potential as a reliable
platform for advanced respiratory support across multiple indications.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dagi Ben-Noon,
Chief Executive Officer of Inspira Technologies, stated: &ldquo;The decision by one of the most decorated and respected medical institutions
in the United </FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">States
to broaden the use of our ART100 system into lung transplantation is a highly meaningful step for Inspira. It reflects the growing confidence
leading hospitals are placing in our technology and underscores its potential to become an essential platform in advanced respiratory
care. This expansion marks an important step toward establishing the ART100 as part of the standard of care in the most complex surgical
settings.&rdquo;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This U.S. clinical expansion follows Inspira&rsquo;s recently announced
multi-million dollar binding government orders for ART100 systems, underscoring the Company&rsquo;s growing global footprint and commercial
momentum.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Inspira Technologies</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inspira Technologies is a commercial-stage medical device company specializing
in advanced respiratory support and real-time blood monitoring solutions. The Company&rsquo;s U.S. Food and Drug Administration -cleared
INSPIRA&trade; ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures
outside the U.S and serves as a foundation for the development of the INSPIRA ART500, a next-generation system designed to deliver oxygenation
while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA&trade;, a proprietary blood sensor
platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining
of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape.
The Company&rsquo;s recent internal shifts may reflect broader alignment with long-term industry trends, including consolidation, cross-sector
collaboration, and potential strategic partnerships. For more information, visit: https://inspira-technologies.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statement Disclaimer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release contains express or implied forward-looking statements
pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of
the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the expanded
use of the ART100 by a leading U.S. hospital, particularly during lung transplant procedures, that the decision to expand the use of the
ART100 during such a complex surgical procedure provides strong external validation of the system&rsquo;s performance and an indication
of its clinical value, that expanding the application of the ART100 into lung transplantation highlights the ART100&rsquo;s potential
as a reliable platform for advanced respiratory support across multiple indications, that the expanded use of the ART100 reflects the
growing confidence leading hospitals are placing in its technology and underscores the ART100&rsquo;s potential to become an essential
platform in advanced respiratory care and that the expansion marks an important step toward establishing the ART100 as part of the standard
of care in the most complex surgical settings. These forward-looking statements and their implications are based solely on the current
expectations of the Company&rsquo;s management and are subject to a number of factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation
to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect
the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained
under the heading &ldquo;Risk Factors&rdquo; in the Company&rsquo;s annual report on Form 20-F for the fiscal year ended December 31, 2024, filed
with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;), which is available on the SEC&rsquo;s website at www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Company Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>Inspira Technologies &ndash; Media Relations<BR>
Email: info@inspirao2.com<BR>
Phone: +972-9-9664485</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Z +L# 2(  A$! Q$!_\0
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7 **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
